Document is current

Article History

Received: 17 December 2024

Accepted: 25 February 2025

First Online: 22 April 2025

Declarations

:

: Alexander Egeberg is currently employed by LEO Pharma and has previously received research funding from Pfizer Inc., AbbVie, Almirall, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Novartis, Janssen, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation; and honoraria as consultant and/or speaker from Pfizer Inc., AbbVie, Amgen, Almirall, Bristol-Myers Squibb, Boehringer Ingelheim, Dermavant, Eli Lilly and Company, Galápagos NV, Galderma, Horizon Therapeutics, Janssen, LEO Pharma, McNeil Consumer Healthcare, Mylan, Novartis, Samsung Bioepis Co., Ltd., Sun Pharmaceuticals, UCB, Union Therapeutics, and Zuellig Pharma Ltd. Thomas Edwards is an employee of Panalgo and received consultancy fees from Pfizer Inc. Jonathan I Silverberg has served as an investigator for Celgene, Eli Lilly and Company, F. Hoffmann-La Roche, Menlo Therapeutics, Realm Therapeutics, Regeneron Pharmaceuticals, and Sanofi Genzyme; as a consultant for Pfizer Inc., AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron Pharmaceuticals, and Sanofi Genzyme; and as a speaker for Regeneron Pharmaceuticals and Sanofi Genzyme. Stephen E Schachterle, Daniela E Myers, and Adina R Lemeshow are employees and shareholders of Pfizer Inc. William Romero is currently employed by Eli Lilly and Company and was an employee and shareholder of Pfizer Inc. at the time of the study. Shefali Vyas is currently employed by AstraZeneca and was an employee and shareholder of Pfizer Inc. at the time of the study.

: This was a retrospective database study and was not subject to ethical review.